Heron Therapeutics (HRTX) grants director 53,960 RSUs vesting 2027

Rhea-AI Filing Summary

Heron Therapeutics director Craig A. Johnson received a grant of 53,960 shares of common stock in the form of restricted stock units. The grant was made on January 30, 2026 at a price of $0 per share, reflecting an equity award rather than an open-market purchase.

The restricted stock units vest in full on January 30, 2027, at which point each unit will convert into one share of common stock. After this grant, Johnson is reported as directly beneficially owning 53,960 shares of Heron Therapeutics common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Johnson Craig A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	53,960	$0.00	--

Holdings After Transaction: Common Stock — 53,960 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Johnson Craig A

(Last) (First) (Middle)

100 REGENCY FOREST DRIVE

SUITE 300

(Street)

CARY NC 27518

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HERON THERAPEUTICS, INC. /DE/ [ HRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		A		53,960(1)	A	$0	53,960	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock.

	/s/Kathryn Lester Attorney-in-fact for Craig A. Johnson	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Heron Therapeutics (HRTX) report for Craig A. Johnson?

Heron Therapeutics reported that director Craig A. Johnson received 53,960 shares of common stock as a restricted stock unit grant. The award was made on January 30, 2026, at a price of $0 per share, reflecting an equity compensation grant rather than a market purchase.

How many Heron Therapeutics (HRTX) shares were granted to the director and at what price?

Craig A. Johnson was granted 53,960 restricted stock units tied to Heron Therapeutics common stock at a price of $0 per share. This represents a stock-based compensation award, increasing his directly beneficially owned position to 53,960 shares following the reported transaction.

When do Craig A. Johnson’s Heron Therapeutics (HRTX) restricted stock units vest?

The restricted stock units granted to director Craig A. Johnson vest in full on January 30, 2027. On that date, each unit will convert into one share of Heron Therapeutics common stock, assuming vesting conditions are satisfied, turning the award into fully owned shares.

Is the Heron Therapeutics (HRTX) Form 4 transaction a purchase or a grant?

The Form 4 discloses a grant, not an open-market purchase. Craig A. Johnson received 53,960 restricted stock units at $0 per share as equity compensation, representing a contingent right to receive one share of common stock for each unit upon vesting in 2027.

How many Heron Therapeutics (HRTX) shares does Craig A. Johnson own after this grant?

Following the reported transaction, Craig A. Johnson is shown as directly beneficially owning 53,960 shares of Heron Therapeutics common stock. This total reflects the newly granted restricted stock units reported on the Form 4 as part of his director compensation package.